Norflex (Orphenadrine Citrate)

Orphenadrine citrate, the active ingredient in Norflex, is a muscle relaxant presented as an oral tablet for oral use. It is employed to relieve muscle spasm and associated musculoskeletal pain in adult patients. GNH USA supplies Norflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orphenadrine citrate acts as a central muscle‑relaxant for conditions involving skeletal muscle spasm. - Muscle spasm: reduces involuntary muscle contraction and associated discomfort. - Musculoskeletal pain: alleviates pain linked to acute musculoskeletal injuries. - Acute low‑back pain: improves mobility and eases tension in the lumbar region.

Orphenadrine citrate may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion causing throat discomfort. - Drowsiness: mild sedation affecting alertness. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Tachycardia: rapid heart rate that may require medical attention. - Urinary retention: difficulty emptying the bladder, particularly in predisposed individuals. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate care. - Hepatic dysfunction: abnormal liver enzymes or jaundice in rare cases.

Before initiating therapy with Orphenadrine citrate, consider the following safety measures. - Cardiac assessment: evaluate history of arrhythmias or heart disease. - Anticholinergic burden: monitor for excessive dry mouth, blurred vision, or constipation. - Elderly patients: use lower doses and observe for confusion or falls. - CNS depressants: avoid concurrent use with alcohol or strong sedatives. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Orphenadrine citrate can interact with several medication classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Tricyclic antidepressants: additive anticholinergic effects. - Other anticholinergics: heightened dry mouth and urinary retention. - CNS depressants: increased sedation and respiratory depression. - Alcohol: potentiates drowsiness and dizziness.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedation. - Beta‑blockers: possible additive effect on heart rate. - Antihypertensives: monitor blood pressure for unexpected changes.